# A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

> **NCT07241390** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 7140 (estimated)

## Conditions studied

- Atherosclerosis Cardiovascular Disease
- Chronic Kidney Disease

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07241390
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 7140 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241390, "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT07241390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*